Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 1;43(5):538-546.
doi: 10.1097/MAO.0000000000003507. Epub 2022 Feb 24.

Cochlear Implantation in Neurofibromatosis Type 2: Experience From the UK Neurofibromatosis Type 2 Service

Matthew E Smith  1 , Rachel Edmiston  1 , Mathieu Trudel  1 , Simon Freeman  1 , Emma Stapleton  1 , Patrick Axon  2 , Neil Donnelly  2 , James R Tysome  2 , Manohar Bance  2 , Rupert Obholzer  3 , Dan Jiang  3 , Samuel Mackeith  4 , James Ramsden  4 , Martin O'Driscoll  1 , Deborah Mawman  1 , Juliette Buttimore  2 , Terry Nunn  3 , Jane Humphries  4 , Dafydd Gareth Evans  5 , Simon K W Lloyd  1   6 ; UK NF2 Research Collaborative
Affiliations

Cochlear Implantation in Neurofibromatosis Type 2: Experience From the UK Neurofibromatosis Type 2 Service

Matthew E Smith et al. Otol Neurotol. .

Abstract

Objective: To review the outcomes of cochlear implants (CI) in patients with neurofibromatosis type 2 (NF2) in a large cohort, and identify factors associated with poor hearing benefit.

Study design: Fifteen-year retrospective national observational case series.

Setting: United Kingdom regional NF2 multidisciplinary teams.

Patients: Consecutive patients with NF2 receiving a CI.

Interventions: CI for hearing rehabilitation.

Main outcome measures: 1) Audiometric performance at 9 to 12 months after implantation using City University of New York (CUNY) sentence recognition score, and Bamford- Kowal-Bench (BKB) word recognition score in quiet (BKBq), and in noise (BKBn). 2) CI use at most recent review.

Results: Sixty four consecutive patients, median age 43 years, were included. Nine to 12 months mean audiometric scores were: CUNY 60.9%, BKBq 45.8%, BKBn 41.6%. There was no difference in audiometric outcomes between VS treatment modalities. At most recent review (median 3.6 years from implantation), 84.9% with device in situ/available data were full or part-time users. Between 9 and 12 months and most recent review there was an interval reduction in mean audiometric scores: CUNY -12.9%, BKBq -3.3%, BKBn -4.9%. Larger tumor size and shorter duration of profound hearing loss were the only variables associated with poorer audiometric scores. Tumor growth at the time of surgery was the only variable associated with CI non-use. Individual patient response was highly variable.

Conclusions: CI can provide significant and sustained auditory benefits to patients with NF2 independent of tumor treatment modality, with the majority of those implanted becoming at least part-time users. Larger datasets are required to reliably assess the role of independent variables.

PubMed Disclaimer

Conflict of interest statement

The authors disclose no conflicts of interest.

References

    1. Evans DG, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 1992; 29:12.
    1. Evans DGR, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 2005; 26:93–97.
    1. Asthagiri AR, Parry DM, Butman JA, et al. Neurofibromatosis type 2. Lancet 2009; 373:1974–1986.
    1. Neary WJ, Hillier VF, Flute T, Stephens D, Ramsden RT, Evans DGR. Use of a closed set questionnaire to measure primary and secondary effects of neurofibromatosis type 2. J Laryngol Otol 2010; 124:720–728.
    1. North HJD, Mawman D, O’Driscoll M, et al. Outcomes of cochlear implantation in patients with neurofibromatosis type 2. Cochlear Implants Int 2016; 17:172–177.

Publication types